4SCAR-T therapy targeting GD2, PSMA and CD276

· Shenzhen Geno-Immune Medical Institute

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 4SCAR-T therapy targeting GD2, PSMA and CD276, covering 2020-11-19 to 2020-11-19. Get the full timeline:

Most recent: Clinical Trial Update: 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma [Phase 1, Phase 2]